HBV Serum Biomarkers Workshop

ICE-HBV is organizing an virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. The event is aimed at scientists, clinicians, pharmaceutical and diagnostic industry representatives.  The workshop, chaired by Anna Kramvis and Peter Revill, is put together by the ICE-HBV serum biomarkers working group. Both classic and future biomarkers will be discussed. The workshop will lead to a consensus statement on promising serum biomarkers. 

The workshop will be divided in two sessions, held on Monday Oct 5 and Monday Oct 12, 2020, via Zoom. Both sessions will start at 12PM GMT, go for approximately 2.5 hours each, and will be recorded.

Free registration is open here.

Background & Objectives:

Functional cure, the loss of HBV surface antigen is the major goal of many HBV cure strategies, using direct acting antivirals and anti-HBV immune-stimulating responses. On the other hand, complete cure involves the elimination or inactivation of the covalently closed circular DNA (cccDNA) reservoir.  As new therapies are developed and tested, there is an urgent need for serum biomarkers that can:

  • accurately correlate with cccDNA expression in the liver,
  • predict HBsAg loss,
  • measure stimulation of host antiviral immune responses
  • screen HBV carriers in order to identify those at high risk of developing hepatocellular carcinoma

Although a number of alternative HBV serum biomarkers have been proposed, including HBV RNA and core related antigen, their clinical relevance, in all settings of chronic HBV infection, has yet to be resolved.

In this workshop, a range of experts will discuss the latest advances and identify knowledge gaps in our understanding of serum biomarkers.  They will discuss challenges that need to be overcome to ensure the utility of various biomarkers in the clinic and for screening new antiviral therapies. Presentations will be complemented by two in-depth discussion panels that will debate these challenges and propose a way forward.


October 5th – 140 Minutes Total – Time in GMT

Session Co-Chairs: Timothy M. Block and Veronica Miller

Noon  Housekeeping Rules Capucine Penicaud
12:00-12:05pm  Welcome and aims of the workshop Anna Kramvis
12:05-12:25pm  Summary of the Viral Serum Biomarker Landscape + Q&As Barbara Testoni
12:25-12:45pm  Summary of Immunological Serum Biomarkers Landscape + Q&As Kyong-Mi Chang
12:45-1pm  What is serum HBV RNA? + Q&As Florian Van Bömmel
1-1:15pm  What is core related antigen? + Q&As Jianming Hu
1:15-1:35pm  Utility of serum biomarkers to follow natural history and treatment of chronic hepatitis B + Q&As Harry Janssen


Panel Co-Chairs: Adam Gehring and Ulrike Protzer

1:35-2:20pm    Industry Panel Discussion – What are the virological and immunological gaps that need to be addressed? What biomarkers are most needed to meet HBV cure endpoints? 


October 12th – 140 Minutes Total – Time in GMT

Session Co-Chairs: Christian Bréchot & Ourania M. Andrisani 

Noon   Housekeeping Rules Capucine Penicaud
12:00-12:10pm  Welcome by Peter Revill & Fabien Zoulim – ICE-HBV Chairmanship Handover   
12:10-12:25pm  Biomarkers of HBV cccDNA expression + Q&As Maura Dandri
12:25-12:40pm  Biomarkers of Occult HBV infection  + Q&As  Theresa Pollicino
12:40-12:55pm  Biomarkers of liver cancer  +Q&As Patrizia Farci
12:55-1:10pm  Point of Care Testing – an unmet and urgent need + Q&As Daryl Lau
1:10-1:30pm  Bench to Bed: Relevance of biomarkers used in in vitro and in vivo model systems to the clinic + QAs Dieter Glebe


Panel Co-Chairs: Fabien Zoulim and Mala Maini

1:30-2:20pm  Industry Panel Discussion: What are the most clinically relevant biomarkers?


2:20-2:30pm  Concluding remarks and next steps Anna Kramvis


This event is endorsed by the HBV International Meeting.